Corix Bioscience, Inc.
CXBS
$0.00
$0.000.00%
OTC PK
| 09/30/2017 | 06/30/2017 | 03/31/2017 | 09/30/2016 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 297.90K | 696.10K | 379.70K | 327.20K | |
| Depreciation & Amortization | 2.10K | -- | -- | 400.00 | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 300.00K | 696.10K | 379.70K | 327.60K | |
| Operating Income | -300.00K | -696.10K | -379.70K | -327.60K | |
| Income Before Tax | -518.60K | -1.48M | -769.20K | -327.60K | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -518.60K | -1.48M | -769.20K | -327.60K | |
| Earnings from Discontinued Operations | -2.62M | -683.30K | -412.20K | -1.22M | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -3.14M | -2.16M | -1.18M | -1.55M | |
| EBIT | -300.00K | -696.10K | -379.70K | -327.60K | |
| EBITDA | -298.70K | -- | -- | -327.40K | |
| EPS Basic | -0.15 | -0.11 | -0.08 | -0.18 | |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | |
| EPS Diluted | -0.15 | -0.11 | -0.08 | -0.18 | |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | |
| Average Basic Shares Outstanding | 20.51M | 19.51M | 14.33M | 8.84M | |
| Average Diluted Shares Outstanding | 20.51M | 19.51M | 14.33M | 8.84M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |